Agreement on Genome-Analysis Technology
Monsanto Company and NRGene announced that they have reached a non-exclusive, multi-year, global licensing agreement on NRGene’s genome-analysis technology.
This enhances Monsanto’s ability to predict, compare and select the best genetic makeup from its vast data sets of genetic, genomic and trait information.
NRGene’s platform, GenoMAGICTM, was developed by a unique mix of experienced algorithm designers, software engineers, plant breeders and plant geneticists and is used by seed companies and major academic and research institutions around the world.
Tom Osborn, Monsanto’s molecular breeding technology director, comments: “Our focus on data is allowing us make better decisions than ever before – and with GenoMAGIC, we expect to provide our plant breeders with a more comprehensive view to improve their analyses and decisions.”
Dr. Gil Ronen, NRGene chief executive officer, says: ”Partnering with companies like Monsanto – combined with our recent achievements, including being the first to map the wheat genome – are significant milestones on our roadmap to become the worldwide leader of genomic big data solutions.”
The use of genome analysis technologies like GenoMAGIC are expected to increase current genetic gain. Monsanto may expand its relationship with NRGene into a longer-term commitment following an in-depth evaluation of the technology. The GenoMAGIC platform extends Monsanto's capabilities for genome selection, trait discovery, and genome enhancement.
Bayer Buys Monsanto for USD66bn
Monsanto and Microsoft to Invest in Agricultural Technology in Brazil
Simplot’s second generation of Innate potatoes receives FDA safety clearance
